Genmab — Maj 2020
-
IMS U.S. weekly gross sales are down ~15% compared to avg. 4W sales as of end of March and are currently at ~$40 million per week*
-
covid impact
-
MM treatment: Short-term delay, not fundamental disruption
-
Limited visibility into RoW sales
-
Det går som forventet
-
Sub Q at home!
-
-
Partner mid year of earlier for Epco
-
Doctors moves patients in amid Covid19
-
Tepezza royalty mid single digit
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind